NMDA antagonist

(redirected from NMDA receptor antagonist)
Also found in: Wikipedia.

NMDA antagonist

Neurology Any of a number of agents that protect against brain damage in neurologic disorders–eg, stroke; PCP–phencyclidine and ketamine are effective, but have psychotomimetic effects or damage neurons in the cerebral cortex; diazepam and barbiturates act at the GABA receptor channel complex, and may prevent the unwanted side effects of NMDA antagonists
References in periodicals archive ?
Early Use of the NMDA Receptor Antagonist Ketamine in Refractory and Superrefractory Status Epilepticus.
One of the preclinical studies evaluated the effects of BTRX-246040 and ketamine, an NMDA receptor antagonist, in non-human primates given a decision-making task or a visuospatial working memory task.
The company's proposed first lead product, QRX001, is a single use transdermal non-competitive NMDA receptor antagonist intended for the treatment of post-surgical pain.
25-27] Peripheral injection of NMDA receptor antagonist attenuates pain associated with neuropathic or inflammatory origin.
There have been several reports on the antidyskinetic effects of amantadine, a nonselective NMDA receptor antagonist.
Some studies on the NMDA receptor antagonist during the early brain development period reported that the chronic blockade of NMDA receptor affected the emotional behaviors and cognitive functions in adults [3, 4].
68-74] Moreover, Patricia and colleagues [75] found that injection of the competitive NMDA receptor antagonist D-AP5 into the dorsal hippocampus impaired the acquisition of context memory without affecting retrieval of fear-related memory.
Effects of the NMDA receptor antagonist ketamine on flavor memory: Conditioned aversion, latent inhibition and habituation of neophobia.
Studies have shown that a single infusion of the NMDA receptor antagonist ketamine produces a very robust response, including full remission, in treatment resistant unipolar or bipolar depression within 1 to 2 hours
2) The best experimental study supporting this hypothesis was conducted in healthy subjects undergoing an NMDA receptor antagonist to reproduce schizophreniform symptoms.
These studies have identified a dose dependent aberrant induction of cell cycle proteins Cyclin-D1, Cyclin-dependent Kinase 4, E2F1 and Bim in primary neurons co-incubated with the NMDA receptor antagonist Ketamine (1).
Memantine (Namenda[TM]) is the only NMDA receptor antagonist approved in the United States.